NCT04002349

Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Beijing Tongren Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.

Conditions

• Determination of the Efficacy of Different Medications for Idiopathic Rhinitis
• Impact of Different Medications on Biomarkers of Idiopathic Rhinitis
• Safety and Tolerance of Different Medications for Idiopathic Rhinitis

Interventions

Type	Name	Description
DRUG	Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)	Detailed in arm descriptions
DRUG	Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)	Detailed in arm descriptions
DRUG	0.9% natural saline	Detailed in arm descriptions

Timeline

• Start date: 2019-07-01
• Primary completion: 2019-12-31
• Completion: 2020-03-31
• First posted: 2019-06-28
• Last updated: 2019-06-28

Locations

2 sites across 1 country: China